RT Journal Article
T1 Differential Antitumoral Properties and Renal-Associated Tissue Damage Induced by Tacrolimus and Mammalian Target of Rapamycin Inhibitors in Hepatocarcinoma: In Vitro and In Vivo Studies.
A1 Navarro-Villarán, Elena
A1 Tinoco, José
A1 Jiménez, Granada
A1 Pereira, Sheila
A1 Wang, Jize
A1 Aliseda, Sara
A1 Rodríguez-Hernández, María A
A1 González, Raúl
A1 Marín-Gómez, Luís M
A1 Gómez-Bravo, Miguel A
A1 Padillo, Francisco J
A1 Álamo-Martínez, José M
A1 Muntané, Jordi
K1 Calcineurina
K1 Carcinoma hepatocelular
K1 División celular
K1 Línea celular
K1 Everolimus
K1 Rechazo del injerto
K1 Hiperbilirrubinemia
K1 Hipertensión portal
K1 Inmunosupresión
K1 Recurrencia neoplásica loca
AB Orthotopic liver transplantation (OLT) is the recommended treatment for patients at early stages of hepatocarcinoma (HCC) with potential portal hypertension and/or bilirubinemia, but without vascular-associated diseases. The patients are receiving immunosuppressive therapy to reduce graft rejection, but differential side effects have been related to calcineurin and mTOR inhibitor administration regarding tumor recurrence and nephrotoxicity. The in vitro studies showed that Tacrolimus exerted a more potent pro-apoptotic effect than Everolimus (Huh 7>Hep 3B>HepG2), being sirolimus only active in Hep3B cell line. Tacrolimus and Everolimus exerted potent antiproliferative properties in Huh 7 and Hep3B in which cells Sirolimus was inactive. Interestingly, Tacrolimus- and Everolimus-dependent G0/G1 cell accumulation occurred as a consequence of drastic reduction in S, as well as in S and G2+M phases, respectively. The in vivo studies support data on the more effective antitumoral properties of Everolimus, eventual risk of pro-angiogenic tumoral properties and nephrotoxicity of Tacrolimus, and pro-proliferative properties of Sirolimus in tumors developed in nude mice.
PB Public Library of Science
YR 2016
FD 2016-08-12
LK http://hdl.handle.net/10668/2436
UL http://hdl.handle.net/10668/2436
LA en
NO Navarro-Villarán E, Tinoco J, Jiménez G, Pereira S, Wang J, Aliseda S, et al. Differential Antitumoral Properties and Renal-Associated Tissue Damage Induced by Tacrolimus and Mammalian Target of Rapamycin Inhibitors in Hepatocarcinoma: In Vitro and In Vivo Studies. PLoS ONE. 2016; 11(8):e0160979
NO Journal Article;
DS RISalud
RD Apr 18, 2025